What we do Samsrita Labs Ltd is a diversified healthcare company focused on bio-pharma, stem cell research, new drug discovery, molecular diagnostics, and clinical research services. |
Founded in 1,996 |
Market share Emerging player in bio-pharma and stem cell research with growing focus on innovative therapies and clinical research services. |
Problem solved Advancing affordable, cutting-edge healthcare solutions in regenerative medicine, diagnostics, and drug development. |
Top clients or who we serve B2B and B2C clients in healthcare, research institutions, hospitals, and pharmaceutical sectors. |
Key management Mr. K. Krishnam Raju (Chairman and Whole-Time Director), Mr. K.N.V. Narendra Kumar (Whole-Time Director). |
Our journey and innovations Founded in 1996, transitioned focus to bio-pharma and stem cells in 2017; collaborations for new drug discovery and clinical research. |
Where we operate Primarily India; expanding into bio-pharma and clinical research sectors with national and international collaborations. |
Top products or what we offer Stem cell therapy, molecular diagnostics, new drug discovery platforms, CRO services, nutraceuticals development, bio-pharma trading. |
Top brands - |
Raw materials needed Medicinal chemicals, biological reagents, APIs required for drug manufacturing and research purposes. |
Raw materials supplier - |
Recurring vs cyclical contribution Currently no commercial revenue, focus on building R&D and bio-pharma capabilities. |
Our industry position Nascent stage with strategic partnerships; aiming to establish foothold in stem cell and bio-pharma sectors. |
Financial highlights No revenue in FY 2024-25; net loss of Rs. 25.95 Lakhs reflecting initial investment and R&D phase. |
Geographical revenue split - |
Order book - |
Whats driving growth Innovation in stem cell therapies, new drug discovery collaborations, expansion into biofuels and green technologies. |
Our future plans Enhance bio-pharma manufacturing, expand clinical research services, enter food processing and IT sectors as per new business objectives. |
Our green promise Committed to pollution control and sustainable operations in line with government regulations. |
Our people and values Small employee base with focus on research excellence, ethical practices, and fostering innovation. |
Key challenges ahead Commercialization hurdles, regulatory approvals, building market presence, and managing legal contingencies. |
Interesting facts Named after Dr. C.M. Habeebullah; shifted focus to innovative biopharma in 2017; has associate companies in biotech space. |
Risks and strategy Risk from R&D investment and legal disputes; strategy includes diversification and strengthening partnerships. |
